## **Condensed Interim Financial Statements**

For the nine months ended September 30, 2021 and 2020

(Expressed in Canadian Dollars)

(Unaudited – Prepared by Management)

## **Corporate Head Office**

Unit 104, 8337 Eastlake Drive Burnaby, BC V5A 4W2

## NOTICE OF NO AUDITOR REVIEW OF INTERIM FINANCIAL STATEMENTS

Under National Instrument 51-102, Part 4, subsection 4.3(3)(a), if an auditor has not performed a review of the interim financial statements, they must be accompanied by a notice indicating that the financial statements have not been reviewed by an auditor.

The accompanying unaudited interim financial statements of the Company have been prepared by and are the responsibility of the Company's management.

The Company's independent auditor has not performed a review of these financial statements in accordance with standards established by the Chartered Professional Accountants of Canada for a review of interim financial statements by an entity's auditor.

## **Condensed Interim Statements of Financial Position**

(Expressed in Canadian dollars)

(Unaudited – Prepared by Management)

	Se	As at eptember 30, 2021	ber 30, December 31	
ASSETS				
Current assets				
Cash	\$	693,034	\$	45,409
Prepaid expenses		21,360		15,890
Receivables (Note 8)		25,279		40,975
		739,673		102,274
Right-of-use asset (Note 6)		80,151		105,026
Property, plant and equipment (Note 3)		59,407		84,794
	\$	879,231	\$	292,094
LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIENCY)				
Current liabilities				
Accounts payable and accrued liabilities (Notes 4, 8)	\$	97,313	\$	227,159
Lease liability (Note 6)		35,400		31,340
Loans payable (Notes 5, 8)		15,015 147,728		15,015 273,514
		,		
Long-term loans payable (Note 5)		40,000		40,000
Long-term lease liability (Note 6)		60,700		87,771
		248,428		401,285
Shareholders' equity (deficiency)				
Share capital (Note 7)		2,640,979		1,743,546
Contribution surplus (Note 7)		495,000		317,000
Deficit		(2,505,176)		(2,169,737)
		630,803		(109,191)
	\$	879,231	\$	292,094

Nature and continuance of operations (Note 1)

**Commitment** (Note 11)

**Subsequent events** (Note 12)

## APPROVED ON BEHALF OF THE DIRECTORS:

"Paul Woodward"	Director	"Jason Moreau"	Director
Paul Woodward		Jason Moreau	

## Aether Catalyst Solutions, Inc. Condensed Interim Statements of Net Loss and Comprehensive Loss

(Expressed in Canadian dollars)

(Unaudited – Prepared by Management)

	Three month period ended,			Nine month period ended,				
	September 30,			September		ptember 30,		
		2021		2020		2021		2020
Expenses								
Amortization (Notes 3, 6)	\$	18,560	\$	12,201	\$	50,262	\$	36,091
Consulting fees (Note 8)		39,560		15,000		69,560		86,170
Interest and accretion (Note 6)		4,385		8,178		13,424		19,903
Office, supplies and miscellaneous		19,410		31,013		51,080		110,443
Filing and issuer fees		5,830		2,421		15,017		13,376
Professional fees		7,865		5,562		28,226		17,631
Rent		931		248		2,794		1,245
Share-based compensation (Notes 7, 8)		-		-		81,600		-
Travel		-		-		-		1,208
Wages and benefits (Note 8)		48,641		76,065		125,721		232,291
		(145,182)		(150,688)		(437,684)		(518,358)
Other income								
Grants and government tax credits		33,713		34,745		102,245		118,664
Gain on settlement of debt		-		10,413		_		10,413
Net loss and comprehensive loss for the								
period	\$	(111,469)	\$	(105,530)	\$	(335,439)	\$	(389,281)
Loss per share – basic and diluted	\$	(0.00)	\$	(0.00)	\$	(0.01)	\$	(0.01)
Weighted average number of shares outstanding – basic and diluted		48,939,167		41,780,764		45,162,768		41,772,060

## **Condensed Interim Statement of Changes in Equity (Deficiency)**

(Expressed in Canadian dollars)

(Unaudited – Prepared by Management)

	Number of			(	Contribution		
	shares	S	hare Capital		Surplus	Deficit	Total
Balance, December 31, 2019	41,746,712	\$	1,553,663	\$	284,000	\$ (1,743,202)	\$ 94,461
Shares issued for warrants	34,000		5,100		-	_	5,100
Shares issued for private placement	260,000		39,000		-	-	39,000
Shares issued for debt	1,041,307		145,783		-	-	145,783
Loss for the period	-		-		-	(389,281)	(389,281)
Balance, September 30, 2020	43,082,019		1,743,546		284,000	(2,132,483)	(104,937)
Shares issued for debt	-		-		33,000	_	33,000
Loss for the period			-		=	(37,254)	(37,254)
Balance, December 31, 2020	43,082,019		1,743,546		317,000	(2,169,737)	(109,191)
Shares issued for private placement	6,160,050		1,078,009		, -	-	1,078,009
Shares issuance cost – cash	-		(84,176)		-	_	(84,176)
Shares issuance cost – broker's warrants	_		(96,400)		96,400	_	
Share-based compensation	-		· · · · ·		81,600	-	81,600
Loss for the period			=		-	(335,439)	(335,439)
Balance, September 30, 2021	49,242,069	\$	2,640,979	\$	495,000	\$ (2,505,176)	\$ 630,803

## Aether Catalyst Solutions, Inc. Condensed Interim Statements of Cash Flows

(Expressed in Canadian dollars)

(Unaudited – Prepared by Management)

	p	Nine month period ended September 30, 2021		Nine month period ended September 30, 2020	
Cash flows from operating activities	ф	(225 420)	¢.	(200 201)	
Net loss for the period	\$	(335,439)	\$	(389,281)	
Changes in non-cash items:		12.007		16 041	
Accretion of lease liability		13,097		16,941	
Amortization		50,262		36,090	
Interest on loans payable		-		3,253	
Share-based compensation		81,600		(10.412)	
Gain on settlement of debt		-		(10,413)	
Changes in non-cash working capital items:		15 (0)		1.070	
Receivables		15,696		1,979	
Prepaid		(5,470)		1,485	
Accounts payable and accrued liabilities		(153,896)		120,871	
Cash used in operating activities		(334,150)		(219,075)	
Cash flows from investing activities Purchase of property, plant and equipment				(8,161)	
Cash used in financing activities		-		(8,161)	
Cash flows from financing activities					
Private placement proceeds		1,078,009		39,000	
Share issuance cost - cash		(84,176)		_	
Lease payments		(36,108)		(35,970)	
Shares issued for warrants exercised		(50,100)		5,100	
Proceeds from loans		24,050		80,000	
Flocecus Holli loans		24,030		80,000	
Cash provided by financing activities		981,775		88,130	
Change in cash		647,625		(139,106)	
Cash, beginning of the period		45,409		145,204	
Cash, end of the period	\$	693,034	\$	6,098	
Supplementary cash flow information					
Non-cash financing activities					
Fair value of brokers warrants	\$	96,400	\$	_	
Shares issued for debt settlement	\$	-	\$	145,783	
Cash paid for interest	\$		\$		
Cash pard for interest	<u> </u>	=	Φ	-	

## **Notes to the Condensed Interim Financial Statements**

(Expressed in Canadian dollars)

(Unaudited – Prepared by Management)

FOR THE PERIOD ENDED SEPTEMBER 30, 2021 AND 2020

#### 1. NATURE AND CONTINUANCE OF OPERATIONS

Aether Catalyst Solutions, Inc. ("Aether" or the "Company") was incorporated under the British Columbia Business Corporations Act ("BCBCA") on July 8, 2011. The Company's principal business activity is commercializing patent pending catalyst technology, first for use in automotive emissions abatement.

These condensed interim financial statements have been prepared on a going concern basis, which presume the realization of assets and discharge of liabilities in the normal course of business for the foreseeable future. The Company's ability to continue as a going concern is dependent upon achieving profitable operations and/or obtaining additional financing.

In assessing whether the going concern assumption is appropriate, management takes into account all available information about the future which is at least, but not limited to, 12 months from December 31, 2020. Management is aware, in making its assessment, of material uncertainties relating to events or conditions that may cast significant doubt upon the Company's ability to continue as a going concern, as explained in the following paragraph.

The Company has sustained losses from operations and does not have sufficient cash to finance its current plans for at least 12 months from the date of this document. The Company expects that it will need to raise substantial additional capital to accomplish its business plan over the next several years. The Company expects to seek additional financing through equity financing. There can be no assurance as to the availability or terms upon which such financing might be available.

In March 2020, there was a global pandemic outbreak of COVID-19. The actual and threatened spread of the virus globally has had a material adverse effect on the global economy and; specifically, the regional economies in which the Company operates. The pandemic could continue to have a negative impact on the stock market, including trading prices of the Company's shares and its ability to raise new capital. These factors, among others, could have a significant impact on the Company's operations

These condensed interim financial statements do not include any adjustments to the amounts and classification of assets and liabilities that might be necessary should the Company be unable to continue in business.

### 2. SIGNIFICANT ACCOUNTING POLICIES

## **Basis of presentation**

### Statement of compliance

These condensed interim financial statements have been prepared on a historical cost basis, except for certain financial instruments that have been measured at fair value. These condensed interim financial statements are prepared using the accrual basis of accounting, except for cash flow information. These condensed interim financial statements are presented in Canadian dollars, which is the functional currency of the Company.

These condensed interim financial statements were approved for issuance by the Company's Board of Directors on November 22, 2021.

These condensed interim financial statements, including comparatives, have been prepared in accordance with IAS 34, Interim Financial Reporting ("IAS 34"), as issued by the International Accounting Standards Boards ("IASB"), and its interpretations, using accounting policies consistent with International Financial Reporting Standards ("IFRS").

## **Notes to the Condensed Interim Financial Statements**

(Expressed in Canadian dollars)

(Unaudited – Prepared by Management)

FOR THE PERIOD ENDED SEPTEMBER 30, 2021 AND 2020

## 2. SIGNIFICANT ACCOUNTING POLICIES (continued)

### Basis of presentation (continued)

The preparation of condensed interim financial statements in accordance with IFRS requires the use of certain critical accounting estimates and judgments when applying the Company's accounting policies. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to the financial statements are disclosed below.

### Use of estimates and judgments

The preparation of these condensed interim financial statements in conformity with IFRS requires management to make judgments and estimates and form assumptions that affect the reported amounts of assets and liabilities at the date of the condensed interim financial statements and reported amounts of revenues and expenses during the reporting periods. On an ongoing basis, management evaluates its judgments and estimates in relation to assets, liabilities, revenue and expenses. Management uses historical experience and various other factors it believes to be reasonable under the given circumstances as the basis for its judgments and estimates. Actual outcomes may differ from these estimates.

## Significant accounting judgments

Significant accounting judgments that management has made in the process of applying accounting policies and that have the most significant effect on the amounts recognized in the financial statements include, but are not limited to, the following:

i) The ability of the Company to continue as a going concern.

### Critical accounting estimates

Key assumptions concerning the future and other key sources of estimation uncertainty that have a significant risk of resulting in a material adjustment to the carrying amount of assets and liabilities within the next financial year include, but are not limited to, the following:

## Income taxes

The Company is periodically required to estimate the tax basis of assets and liabilities. Where applicable tax laws and regulations are either unclear or subject to varying interpretations, it is possible that changes in these estimates could occur that materially affect the amounts of deferred income tax assets and liabilities recorded in the financial statements.

Changes in deferred tax assets and liabilities generally have a direct impact on earnings in the period that the changes occur. Each period, the Company evaluates the likelihood of whether some portion or all of each deferred tax asset will not be realized. This evaluation is based on historic and future expected levels of taxable income, the pattern and timing of reversals of taxable temporary timing differences that give rise to deferred tax assets and liabilities, and tax planning initiatives.

## Cash and cash equivalents

Cash and cash equivalents consist of cash held with banks and highly liquid short-term investments in high interest saving accounts which can be withdrawn at any time, which, in the opinion of management, is subject to an insignificant risk of changes in value. As at September 30, 2021 and 2020, the Company held only cash.

## **Notes to the Condensed Interim Financial Statements**

(Expressed in Canadian dollars)

(Unaudited – Prepared by Management)

FOR THE PERIOD ENDED SEPTEMBER 30, 2021 AND 2020

## 2. SIGNIFICANT ACCOUNTING POLICIES (continued)

#### **Income taxes**

Income tax expense comprises current and deferred tax. Current tax and deferred tax are recognized in profit or loss except to the extent that it relates to a business combination or items recognized directly in equity.

Current income taxes are recognized for the estimated income taxes payable or receivable on taxable income or loss for the current year and any adjustment to income taxes payable in respect of previous years. Current income taxes are determined using tax rates and tax laws that have been enacted or substantively enacted by the year-end date.

Deferred tax assets and liabilities are recognized where the carrying amount of an asset or liability differs from its tax base, except for taxable temporary differences arising on the initial recognition of goodwill and temporary differences arising on the initial recognition of an asset or liability in a transaction which is not a business combination and at the time of the transaction affects neither accounting nor taxable profit or loss.

Recognition of deferred tax assets for unused tax losses, tax credits and deductible temporary differences is restricted to those instances where it is probable that future taxable profit will be available against which the deferred tax asset can be utilized. At the end of each reporting period the Company reassesses unrecognized deferred tax assets. The Company recognizes a previously unrecognized deferred tax asset to the extent that it has become probable that future taxable profit will allow the deferred tax asset to be recovered.

#### Financial instruments

Financial assets are classified at initial recognition as: amortized cost, fair value through profit or loss ("FVTPL"), or fair value through other comprehensive income ("FVTOCI"). The classification depends on the Company's business model for managing the financial assets and the contractual cash flow characteristics. For assets measured at fair value, gains and losses will either be recorded in profit or loss or OCI.

Fair value through profit or loss ("FVTPL") – Financial assets carried at FVTPL are initially recorded at fair value and transaction costs are expensed in the income statement. Realized and unrealized gains and losses arising from changes in the fair value of the financial asset held at FVTPL are included in the income statement in the period in which they arise. Derivatives are also categorized as FVTPL unless they are designated as hedges.

Fair value through other comprehensive income ("FVTOCI") - Investments in equity instruments at FVTOCI are initially recognized at fair value plus transaction costs. Subsequently, they are measured at fair value, with gains and losses arising from changes in fair value recognized in other comprehensive income. There is no subsequent reclassification of fair value gains and losses to profit or loss following the derecognition of the investment.

Financial assets at amortized cost - A financial asset is measured at amortized cost if the objective of the business model is to hold the financial asset for the collection of contractual cash flows, and the asset's contractual cash flows are comprised solely of payments of principal and interest. They are classified as current assets or non-current assets based on their maturity date and are initially recognized at fair value and subsequently carried at amortized cost less any impairment.

Derivatives embedded in contracts where the host is a financial asset in the scope of the standard are never separated. Instead, the hybrid financial instrument as a whole is assessed for classification.

## **Notes to the Condensed Interim Financial Statements**

(Expressed in Canadian dollars)

(Unaudited – Prepared by Management)

FOR THE PERIOD ENDED SEPTEMBER 30, 2021 AND 2020

## 2. SIGNIFICANT ACCOUNTING POLICIES (continued)

### Financial instruments (continued)

Financial liabilities are measured at amortized cost, unless they are required to be measured at FVTPL or the Company has opted to measure at FVTPL. The following table summarizes the classification and measurement changes under IFRS 9 for each financial instrument:

Financial Assets and Liabilities	IFRS 9
	Classification and
	Measurement
Cash	FVTPL
Accounts payable and accrued liabilities	Amortized cost
Loans payable	Amortized cost
Lease liability	Amortized cost

### Measurement

Financial assets and liabilities at FVTPL are initially recognized at fair value and transaction costs are expensed in profit or loss. Realized and unrealized gains and losses arising from changes in the fair value of the financial assets or liabilities held at FVTPL are included in profit or loss in the period in which they arise. Where the Company has opted to designate a financial liability at FVTPL, any changes associated with the Company's credit risk will be recognized in OCI.

Financial assets and liabilities at amortized cost are initially recognized at fair value, and subsequently carried at amortized cost less any impairment.

## *Impairment*

The Company assesses on a forward-looking basis the expected credit loss ("ECL") associated with financial assets measured at amortized cost, contract assets and debt instruments carried at FVOCI. The impairment methodology applied depends on whether there has been a significant increase in credit risk.

An impairment loss in respect of a financial asset measured at amortized cost is calculated as the difference between its carrying amount and the present value of the estimated future cash flows discounted at the asset's original effective interest rate. Losses are recognized in profit or loss and reflected in an allowance account against receivables. When a subsequent event causes the amount of impairment loss to decrease, the decrease in impairment loss is reversed through profit or loss.

#### **Government contributions**

Government funding of eligible research and development expenditures is recognized when there is reasonable assurance that the Company will comply with the conditions attached to the grant and the grant will be received. The Company presents the grant in the statement of comprehensive loss. Tax credits are recognized in the statement of comprehensive loss when received.

### **Segment reporting**

An operating segment is a component of the Company that engages in business activities from which it may earn revenues and incur expenses. The operating segment's operating result is reviewed regularly by the Company's management, including the Chief Executive Officer, to make decisions about resources to be allocated to the segment, assess its performance, and for which discrete financial information is available.

## **Notes to the Condensed Interim Financial Statements**

(Expressed in Canadian dollars)

(Unaudited – Prepared by Management)

FOR THE PERIOD ENDED SEPTEMBER 30, 2021 AND 2020

## 2. SIGNIFICANT ACCOUNTING POLICIES (continued)

### Property, plant and equipment

Property, plant and equipment is stated at historical cost less accumulated depreciation and accumulated impairment losses. Property, plant and equipment is depreciated over its estimated useful lives. The cost of an item includes the purchase price and directly attributable costs to bring the asset to the location and condition necessary for it to be capable of operating in the manner intended by management. Where an item of property, plant and equipment comprises major components with different useful lives, the components are accounted for as separate items of property, plant and equipment.

Subsequent costs are included in the asset's carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably. The carrying amount of the replaced part is derecognized. All other repairs and maintenance are charged to the statement of income and comprehensive income during the financial period in which they are incurred.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognized in profit or loss.

Depreciation is recognized using the following rate and method:

Equipment straight-line over 5 years

Leasehold improvement straight-line over remaining lease term

Depreciation methods, useful lives and residual values are reviewed at each financial year end and are adjusted if appropriate. Plant and equipment costs are not amortized until the asset is available for use.

### Impairment of non-financial assets

The carrying amount of the Company's property, plant and equipment is reviewed at each reporting date to determine whether there is any indication of impairment. If such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss. An impairment loss is recognized whenever the carrying amount of an asset or its cash generating unit exceeds its recoverable amount. Impairment losses are recognized in the statement of net loss and comprehensive loss.

### Share capital

The proceeds from the exercise of stock options and warrants are recorded as share capital in the amount for which the option or warrant enabled the holder to purchase a share in the Company. The Company's common shares are classified as equity instruments.

Commissions paid to agents, and other directly attributable share issuance costs, such as legal, auditing, and printing, on the issue of the Company's shares are charged directly to share capital.

When units are issued during a private placement, which include both common shares and share purchase warrants, the warrants are valued by comparing the total unit price to the fair value of the shares on the day of the announcement of the private placement. Any premium above the fair value of the shares issued would be allocated to the warrants and credited to the warrant reserve.

## **Notes to the Condensed Interim Financial Statements**

(Expressed in Canadian dollars)

(Unaudited – Prepared by Management)

FOR THE PERIOD ENDED SEPTEMBER 30, 2021 AND 2020

## 2. SIGNIFICANT ACCOUNTING POLICIES (continued)

### Loss per share

Basic loss per share is computed by dividing the loss for the year by the weighted average number of common shares outstanding during the year. Diluted loss per share reflects the potential dilution that could occur if potentially dilutive securities were exercised or converted to common stock. The dilutive effect of options and warrants and their equivalent is computed by application of the treasury stock method. Fully diluted amounts are not presented when the effect of the computations are anti-dilutive due to the losses incurred.

## **Share-based payments**

Where equity settled share purchase options are awarded to employees, the fair value of the options at the date of grant is charged to profit or loss over the vesting period using the graded vesting method. Performance vesting conditions are taken into account by adjusting the number of equity instruments expected to vest at each reporting date so that, ultimately, the cumulative amount recognized over the vesting period is based on the number of options that eventually vest. Non-vesting conditions and market vesting conditions are factored into the fair value of the options granted. As long as all other vesting conditions are satisfied, a charge is made irrespective of whether these vesting conditions are satisfied. The cumulative expense is not adjusted for failure to achieve a market vesting condition or where a non-vesting condition is not satisfied. Where the terms and conditions of options are modified before they vest, the increase in the fair value of the options, measured immediately before and after the modification, is also charged to profit or loss over the remaining vesting period.

Where equity instruments are granted to non-employees, they are recorded at the fair value of the goods or services received, unless they are related to the issuance of shares. Amounts related to the issuance of shares are recorded as a reduction of share capital.

When the value of goods or services received in exchange for the share-based payments cannot be reliably estimated, the fair value is measured by use of a valuation model. The expected life used in the model is adjusted, based on management's best estimate, for the effects of non-transferability, exercise restrictions and behavioral considerations.

All equity-settled share-based payments are reflected in share-based payment reserve, until exercised. Upon exercise, shares are issued from treasury and the amount reflected in share-based payment reserve is credited to share capital, adjusted for any consideration paid.

Where a grant of options is cancelled or settled during the vesting period, excluding forfeitures when vesting conditions are not satisfied, the Company immediately accounts for the cancellation as an acceleration of vesting and recognizes the amount that otherwise would have been recognized for services received over the remainder of the vesting period. Any payment made to the employee on the cancellation is accounted for as the repurchase of an equity interest, except to the extent the payment exceeds the fair value of the equity instrument granted, measured at the repurchase date. Any such excess is recognized as an expense.

#### Leases

At inception of a contract, the Company assesses whether the contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

## **Notes to the Condensed Interim Financial Statements**

(Expressed in Canadian dollars)

(Unaudited – Prepared by Management)

FOR THE PERIOD ENDED SEPTEMBER 30, 2021 AND 2020

## 2. SIGNIFICANT ACCOUNTING POLICIES (continued)

### Leases (continued)

Leases of right-of-use assets are recognized at the lease commencement date at the present value of the lease payments that are not paid at that date. The lease payments are discounted using the interest rate implicit in the lease, if that rate can be readily determined, and otherwise at the Company's incremental borrowing rate. At the commencement date, a right-of-use asset is measured at cost, which is comprised of the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any decommissioning and restoration costs, less any lease incentives received.

Each lease payment is allocated between repayment of the lease principal and interest. Interest on the lease liability in each period during the lease term is allocated to produce a constant periodic rate of interest on the remaining balance of the lease liability. Except where the costs are included in the carrying amount of another asset, the Company recognizes in profit or loss (a) the interest on a lease liability and (b) variable lease payments not included in the measurement of a lease liability in the period in which the event or condition that triggers those payments occurs. The Company subsequently measures a right-of-use asset at cost less any accumulated depreciation and any accumulated impairment losses; and adjusted for any remeasurement of the lease liability. Right-of-use assets are depreciated over the shorter of the asset's useful life and the lease term, except where the lease contains a bargain purchase option a right-of-use asset is depreciated over the asset's useful life.

### New accounting standards

Accounting standards not yet effective

## Classification of Liabilities as Current or Non-current (Amendments to IAS 1)

The amendments to IAS1 provide a more general approach to the classification of liabilities based on the contractual arrangements in place at the reporting date.

These amendments are effective for reporting periods beginning on or after January 1, 2023 and are expected to have no impact on the Company.

## **Notes to the Condensed Interim Financial Statements**

(Expressed in Canadian dollars)

(Unaudited – Prepared by Management)

FOR THE PERIOD ENDED SEPTEMBER 30, 2021 AND 2020

## 3. PROPERTY, PLANT AND EQUIPMENT

	Total	
Cost		
Balance, December 31, 2019	\$ 70,695	
Addition	61,421	
Balance, December 31, 2020	132,116	
Additions	-	
Balance, September 30, 2021	\$ 132,116	
Amortization		
Balance, December 31, 2019	\$ 25,075	
Amortization	22,247	
Balance, December 31, 2020	47,322	
Amortization	25,387	
Balance, September 30, 2021	\$ 72,709	
Net Book Value, December 31, 2020	\$ 84,794	
Net Book Value, September 30, 2021	\$ 59,407	

#### 4. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

Payables and accrued liabilities for the Company are broken down as follows:

	Septem	ber 30, 2021	I	December 31, 2020
Trade payables Accrued liabilities Due to government Due to related parties (Note 8)		71,363 10,950 - 15,000	\$	105,659 15,600 28,424 77,476
Total	\$	97,313	\$	227,159

### 5. LOANS PAYABLE

During the year ended December 31, 2018, the Company received non-interest bearing loans with no fixed terms of repayment totaling \$51,710. The Company repaid \$24,000 of the loan payable during the year ended December 31, 2018. The Company settled the debt in full during the year ended December 31, 2020.

During the year ended December 31, 2017, the Company received non-interest bearing unsecured loans with no fixed terms of repayment totaling \$15,800. The Company repaid \$8,500 during the year ended December 31, 2017 and \$5,000 during the year ended December 31, 2018. There is a balance of \$2,300 remaining at September 30, 2021 (December 31, 2020 – \$2,300).

During the year ended December 31, 2020, the Company entered into a \$40,000 promissory note with a company controlled by the Chief Financial Officer of the Company for a period of 6 months at an interest rate of 15% per annum. The Company settled the debt in full during the year ended December 31, 2020.

## **Notes to the Condensed Interim Financial Statements**

(Expressed in Canadian dollars)

(Unaudited – Prepared by Management)

FOR THE PERIOD ENDED SEPTEMBER 30, 2021 AND 2020

## 5. LOANS PAYABLE (continued)

During the year ended December 31, 2020, the Company received non-interest bearing loans with no fixed terms of repayment totaling \$12,715.

During the year ended December 31, 2020, the Company received an interest-free loan of \$60,000 through Canada Emergency Business Account. Repaying the balance of the loan on or before December 31, 2022 will result in loan forgiveness of \$20,000. If the balance is not paid by December 31, 2022, the remaining balance will be converted to a 3-year term loan at 5% annual interest, effective January 1, 2023. As at December 31, 2020, \$20,000 has been recognized as a gain.

### 6. LEASES

The following is the lease liabilities recognized at March 1, 2019:

Lease entered into on March 1, 2019 before discounting Discounted using incremental borrowing rate of 16%	\$ 239,263 (73,433)
Total lease liabilities recognized under IFRS 16 at March 1, 2019	\$ 165,830

For the period ending September 30, 2021 depreciation of the right of use asset was \$24,875 (December 31, 2020 - \$33,166). The right of use asset is depreciated on a straight-line basis over the term of the lease.

Right of use asset, December 31, 2019	\$ 138,192
Depreciation of right of use asset	(33,166)
Right of use asset, December 31, 2020	105,026
Depreciation of right of use asset	(24,875)
Right of use asset, September 30, 2021	\$ 80,151

For the period ending September 30, 2021, finance charges on the lease liability were \$13,097 (December 31, 2020 - \$21,356). The lease term matures on February 29, 2024.

Balance, December 31, 2019	\$	145,003
Lease payments		(47,248)
Accretion		21,356
Balance, December 31, 2020		119,111
Lease payments		(36,108)
Accretion		13,097
Balance, September 30, 2021	\$	96,100
Current lease liability		35,400
Long-term lease liability		60,700
Total lease liability at September 30, 2021	\$	96,100
	·	•

### **Notes to the Condensed Interim Financial Statements**

(Expressed in Canadian dollars)

(Unaudited – Prepared by Management)

FOR THE PERIOD ENDED SEPTEMBER 30, 2021 AND 2020

#### 7. SHARE CAPITAL

#### Authorized

Unlimited common shares without par value

#### Issued

During the period ended September 30, 2021, the Company:

- i) completed a first tranche of its non-brokered private placement and issued 4,169,550 units at a price of \$0.175 per unit for gross aggregate proceeds of \$729,671. Each unit consists of one common share and one common share purchase warrant exercisable at \$0.225 for a period of 24 months.
  - The Company paid finder's fees of \$57,709 and issued 400,947 finders' warrants (valued at \$54,700), entitling the holder thereof to purchase one unit of the company at a price of \$0.175 per warrant share for a period of 24 months.
- ii) completed the final tranche of its non-brokered private placement and issued 1,990,500 units at a price of \$0.175 per unit for gross aggregate proceeds of \$348,338. Each unit consists of one common share and one common share purchase warrant exercisable at \$0.225 for a period of 24 months.

The Company paid finder's fees of \$26,467 and issued 189,050 finders' warrants (valued at \$41,700), entitling the holder thereof to purchase one unit of the company at a price of \$0.175 per warrant share for a period of 24 months.

During the year ended December 31, 2020, the Company:

- i) issued 34,000 shares for total proceeds of \$5,100 for warrants exercised.
- ii) issued 260,000 units for gross proceeds of \$39,000. Each unit consists of one common share and one-half common share purchase warrant exercisable at \$0.25 for a period 12 months.
- iii) issued 1,041,307 units valued at \$178,783 to settle \$156,196 of debt with related parties and non-related parties resulting in a loss of \$22,587. Each unit consists of one common share and one-half common share purchase warrant exercisable at \$0.25 for a period 12 months.

#### **Escrow shares**

On March 31, 2019, the Company entered into a share escrow agreement where a total of 34,673,338 shares were initially held in escrow to be released according to a pre-determined release schedule. As at September 30, 2021, there were 10,401,999 shares in escrow (December 31, 2020 - 15,603,000).

## **Notes to the Condensed Interim Financial Statements**

(Expressed in Canadian dollars)

(Unaudited – Prepared by Management)

FOR THE PERIOD ENDED SEPTEMBER 30, 2021 AND 2020

## 7. SHARE CAPITAL (continued)

### **Options**

A summary of changes in options during the period is as follows:

	Number of Options	Weighted exerc	average
Outstanding, December 31, 2019	1,900,000	\$	0.20
Cancelled	(150,000)		0.20
Outstanding, December 31, 2020	1,750,000		0.20
Granted	1,350,000		0.10
Cancelled	(600,000)		0.20
Outstanding, September 30, 2021	2,500,000	\$	0.15

The following options were outstanding at September 30, 2021:

Number of Options	Exercise Price	Expiry Date
1,350,000	\$0.10	January 8, 2023
1,150,000	\$0.20	November 28, 2024
2,500,000		

Share-based compensation

During the period ended September 30, 2021, the Company granted 1,350,000 stock options valued at \$81,600 to certain directors, officers, and employees of the Company. The options are exercisable at a price of \$0.10 per share expiring on January 8, 2023.

The following weighted average assumptions were used for the Black-Scholes option pricing model valuation of options granted for the period ended September 30, 2021 and the year ended December 31, 2020:

	Period ended September 30, 2021	Year ended December 31, 2020
Risk-free interest rate	0.18%	-
Expected life of options	2 years	-
Expected annualized volatility	120%	-
Exercise price	\$0.10	-
Expected dividend rate	0.00%	-

## **Notes to the Condensed Interim Financial Statements**

(Expressed in Canadian dollars)

(Unaudited – Prepared by Management)

FOR THE PERIOD ENDED SEPTEMBER 30, 2021 AND 2020

## 7. SHARE CAPITAL (continued)

#### Warrants

During the period ended September 30, 2021, the Company:

- i) granted 4,169,550 warrants pursuant to the first tranche of private placement. The warrants are exercisable at a price of \$0.225 per share expiring on June 23, 2023. The Company used the residual method to value the warrants, resulting in a value attributed to warrants of \$Nil.
- ii) granted 1,990,500 warrants pursuant to the final tranche of private placement. The warrants are exercisable at a price of \$0.225 per share expiring on July 14, 2023. The Company used the residual method to value the warrants, resulting in a value attributed to warrants of \$Nil.

A summary of changes in warrants during the period is as follows:

	Number of Warrants	Weighted average exercise price		
Outstanding, December 31, 2019	2,250,000	\$	0.15	
Granted - expiring on September 29, 2021	650,653	*	0.25	
Expired	(2,216,000)		0.15	
Exercised	(34,000)		0.15	
Outstanding, December 31, 2020	650,653		0.25	
Granted	6,160,050		0.23	
Expired	(650,653)		0.25	
Outstanding, September 30, 2021	6,160,050	\$	0.23	

Number of Warrants	Exercise Price	Expiry Date
4,169,550*	\$0.225	June 23, 2023
1,990,500	\$0.225	July 14, 2023
6,160,050		

<sup>\*100,000</sup> warrants exercised subsequently

## **Notes to the Condensed Interim Financial Statements**

(Expressed in Canadian dollars)

(Unaudited – Prepared by Management)

FOR THE PERIOD ENDED SEPTEMBER 30, 2021 AND 2020

## 7. SHARE CAPITAL (continued)

### **Brokers Warrants**

During the period ended September 30, 2021, the Company:

- i) granted 400,947 brokers warrants valued at \$54,700 pursuant to the first tranche of private placement. The warrants are exercisable into units at a price of \$0.175 per unit expiring on June 23, 2023. Each unit will consist of a common share and a warrant exercisable at a price of \$0.225 for a period of 24 months.
- ii) granted 189,050 brokers warrants valued at \$41,700 pursuant to the final tranche of private placement. The warrants are exercisable into units at a price of \$0.175 per unit expiring on July 14, 2023. Each unit will consist of a common share and a warrant exercisable at a price of \$0.225 for a period of 24 months.

A summary of changes in broker warrants during the period is as follows:

	Number of Broker Warrants		Weighted average exercise price		
Outstanding, December 31, 2020 and 2019 Granted	- 589,997	\$	0.18		
Outstanding, September 30, 2021	589,997	\$	0.18		

Number of Broker Warrants	Exercise Price	Expiry Date
400,947*	\$0.175	June 23, 2023
189,050**	\$0.175	July 14, 2023
589,997		

<sup>\*19,200</sup> broker warrants exercised subsequently

The following weighted average assumptions were used for the Black-Scholes option pricing model valuation of agent warrants granted for the period ended September 30, 2021 and the year ended December 31, 2020:

	Period ended September 30, 2021	Year ended December 31, 2020
Risk-free interest rate	0.43%	-
Expected life of options	2 years	_
Expected annualized volatility	165%	-
Exercise price	\$0.191	-
Expected dividend rate	0.00%	-

<sup>\*76,525</sup> broker warrants exercised subsequently

### **Notes to the Condensed Interim Financial Statements**

(Expressed in Canadian dollars)

(Unaudited – Prepared by Management)

FOR THE PERIOD ENDED SEPTEMBER 30, 2021 AND 2020

#### 8. RELATED PARTY TRANSACTIONS

	Period ended September 30, 2021		Period ended September 30, 2020	
Transactions with Key Management Personnel				
Consulting fees paid to a director, officers, a company with				
common directors and a company owned by a director and officer	\$	45,000	\$	45,000
Wages paid to officers	\$	46,500	\$	75,000
Share-based compensation to officers and directors	\$	66,489	\$	-

As at September 30, 2021, accounts payable and accrued liabilities include \$15,768 (December 31, 2020 – \$77,296) owing to a company owned by a director, officers and companies with common directors. The amounts are unsecured, non-interest bearing and have no specific terms of repayment.

As at September 30, 2021, other receivable includes \$3,450 (December 31, 2020 – \$24,688) owing from companies with common directors. The amounts are unsecured, non-interest bearing and have no specific terms of repayment.

As at September 30, 2021, loans payable included \$15,015 (December 31, 2020 – \$15,015) owing to companies with a director in common.

### 9. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT

Fair Value Hierarchy

Financial instruments recorded at fair value on the Statement of Financial Position are classified using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. The fair value hierarchy has the following levels:

Level 1 – valuation based on quoted prices (unadjusted) in active markets for identical assets or liabilities;

Level 2 – valuation techniques based on inputs other than quoted prices included in level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and

Level 3 – valuation techniques using inputs for the asset or liability that are not based on observable market data (unobservable inputs).

The fair value hierarchy requires the use of observable market inputs whenever such inputs exist. A financial instrument is classified to the lowest level of the hierarchy for which a significant input has been considered in measuring fair value.

The Company's risk exposures and the impact on the Company's financial instruments are summarized below:

Credit Risk

Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. The Company's cash is exposed to credit risk. The Company reduces its credit risk on cash by placing these instruments with institutions of high credit worthiness. As at September 30, 2021, the Company is not exposed to any significant credit risk.

## **Notes to the Condensed Interim Financial Statements**

(Expressed in Canadian dollars)

(Unaudited – Prepared by Management)

FOR THE PERIOD ENDED SEPTEMBER 30, 2021 AND 2020

## 9. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (continued)

Foreign Exchange Risk

Foreign exchange risk is the risk that the fair value of future cash flows will fluctuate as a result of changes in foreign exchange rate. The Company does not believe it is exposed to significant currency risk as funds are held in Canadian currency and there are no significant foreign exchange currency transactions.

Interest Rate Risk

Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company is exposed to the risk that the value of financial instruments will change due to movement in market interest rates. The Company does not hold interest-bearing debt with long-term maturities and therefore does not believe that interest rate risk is significant. The Company does not use derivative instruments to reduce its interest rate risk as the Company's management believes that the likely financial impact of interest rate changes does not justify using derivatives.

Liquidity Risk

Liquidity risk is the risk that the Company will encounter difficulty in meeting obligations associated with the Company's financial liabilities. The Company manages liquidity risk by maintaining sufficient cash balances to enable settlement of transactions on the due date. Accounts payable and accrued liabilities are current. The Company addresses its liquidity risk through equity financing obtained through the sale of common shares and the exercise of warrants and options.

### 10. CAPITAL MANAGEMENT

The Company's objective when managing capital is to safeguard the Company's ability to continue as a going concern, so that it can continue to provide returns for shareholders and benefits for other stakeholders.

The Company considers the items included in shareholders' equity as capital. The Company manages the capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of the underlying assets. In order to maintain or adjust the capital structure, the Company may issue new shares through private placements, sell assets to reduce debt or return capital to shareholders. There were no changes in the Company's approach to capital management during the period ended September 30, 2021. The Company is not subject to externally imposed capital requirements.

### 11. COMMITMENT

The Company has entered into lease agreement for a premise expiring February 29, 2024.

Future minimum annual lease payments for the next four years and beyond are as follows:

2021	\$ 8,182
2022	32,727
2023	32,727
2024	5,455
	\$ 79,091

## **Notes to the Condensed Interim Financial Statements**

(Expressed in Canadian dollars)

(Unaudited – Prepared by Management)

FOR THE PERIOD ENDED SEPTEMBER 30, 2021 AND 2020

## 12. SUBSEQUENT EVENTS

Subsequent to the period ended September 30, 2021, the Company:

- i) issued 100,000 shares for total proceeds of \$22,500 for warrants exercised.
- ii) issued 95,725 units for total proceeds of \$16,752 for broker warrants exercised. Each unit consists of a common share and a warrant exercisable at a price of \$0.225 for a period of 24 months.